5374 related articles for article (PubMed ID: 6191673)
41. Studies on auromomycin.
Yamashita T; Naoi N; Hidaka T; Watanabe K; Kumada Y; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1979 Apr; 32(4):330-9. PubMed ID: 468720
[TBL] [Abstract][Full Text] [Related]
42. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.
Watanabe M; Komeshima N; Naito M; Isoe T; Otake N; Tsuruo T
Cancer Res; 1991 Jan; 51(1):157-61. PubMed ID: 1988080
[TBL] [Abstract][Full Text] [Related]
43. [The antitumor activity of liposomal aclarubicin in vitro and in vivo].
Viadro MM; Navashin SM
Biull Eksp Biol Med; 1991 Nov; 112(11):523-5. PubMed ID: 1810495
[TBL] [Abstract][Full Text] [Related]
44. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
45. [Effect of aclacinomycin B on DNA polymerase II of tumor cells].
Li ZR; Feng JB; Han R; Yin MB; Xia LJ
Zhongguo Yao Li Xue Bao; 1985 Sep; 6(3):189-92. PubMed ID: 2943125
[No Abstract] [Full Text] [Related]
46. [Models of preclinical studies of anthracyclines].
Fizames C
Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
[TBL] [Abstract][Full Text] [Related]
47. Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
Konishi M; Sugawara K; Kofu F; Nishiyama Y; Tomita K; Miyaki T; Kawaguchi H
J Antibiot (Tokyo); 1986 Jun; 39(6):784-91. PubMed ID: 3733527
[TBL] [Abstract][Full Text] [Related]
48. Saframycin S, a new saframycin group antibiotic.
Mikami Y; Yokoyama K; Tabeta H; Nakagaki K; Arai T
J Pharmacobiodyn; 1981 Apr; 4(4):282-6. PubMed ID: 7264873
[TBL] [Abstract][Full Text] [Related]
49. Gilvocarcins, new antitumor antibiotics. 3. Antitumor activity.
Morimoto M; Okubo S; Tomita F; Marumo H
J Antibiot (Tokyo); 1981 Jun; 34(6):701-7. PubMed ID: 6792176
[TBL] [Abstract][Full Text] [Related]
50. [Optimal administration schedules of antineoplastic antibiotics based on their pharmacokinetics, with special reference to bleomycins and anthracyclines].
Ota K; Goto T; Fukushima M; Ariyoshi Y
Gan To Kagaku Ryoho; 1982 Aug; 9(8):1352-61. PubMed ID: 6191712
[TBL] [Abstract][Full Text] [Related]
51. Tetrocarcins, new antitumor antibiotics. 3. Antitumor activity of tetrocarcin A.
Morimoto M; Fukui M; Ohkubo S; Tamaoki T; Tomita F
J Antibiot (Tokyo); 1982 Aug; 35(8):1033-7. PubMed ID: 7142004
[TBL] [Abstract][Full Text] [Related]
52. Effects of hyperthermia and ethanol on the cytotoxicity of bleomycin, adriamycin, cis-diamminedichloroplatinum(II) and macromomycin toward hela cells.
Ishida A; Mizuno S
Gan; 1982 Feb; 73(1):129-31. PubMed ID: 6180950
[TBL] [Abstract][Full Text] [Related]
53. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
54. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
55. Biological activity of macromomycin.
Hidaka T; Yano Y; Yamashita T; Watanabe K
J Antibiot (Tokyo); 1979 Apr; 32(4):340-6. PubMed ID: 468721
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
57. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
58. Enhancement of pyrimidine nucleoside uptake into K562 and YAC-1 cells by cadeguomycin.
Wu RT; Okabe T; Kim SH; Suzuki H; Tanaka N
J Antibiot (Tokyo); 1985 Nov; 38(11):1588-95. PubMed ID: 2416726
[TBL] [Abstract][Full Text] [Related]
59. Experimental and clinical studies on aclarubicin in the treatment of solid tumors.
Kumai K; Kubota T; Ishibiki K; Abe O
Biomed Pharmacother; 1984; 38(7):332-7. PubMed ID: 6596963
[TBL] [Abstract][Full Text] [Related]
60. Fredericamycin A, a new antitumor antibiotic. II. Biological properties.
Warnick-Pickle DJ; Byrne KM; Pandey RC; White RJ
J Antibiot (Tokyo); 1981 Nov; 34(11):1402-7. PubMed ID: 7319903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
